Cargando...

Improving the Efficacy of Radioimmunotherapy for Non-Hodgkin’s Lymphomas

Approximately 66,000 Americans develop non-Hodgkin’s lymphomas (NHL) each year. Although the use of unlabeled antibodies such as rituximab has significantly improved survival when combined with standard chemotherapy regimens, two-thirds of lymphoma patients eventually relapse and succumb to their di...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Palanca-Wessels, M. Corinna A., Press, Oliver W.
Formato: Artigo
Idioma:Inglês
Publicado: 2010
Assuntos:
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC2820155/
https://ncbi.nlm.nih.gov/pubmed/20127945
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.24801
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!